Tag: Epidiolex

FDA Expands GW Pharma’s Epidiolex Label

FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex – Age-range for all EPIDIOLEX indications expanded to include patients one year of age and...
- August 3rd, 2020 at 7:35 am

GW Pharma Generates $109 Million Revenue in Q4

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full...
- February 25th, 2020 at 4:24 pm

GW Pharma Reveals Epidiolex Pricing

GW Pharmaceuticals (NASDAQ: GWPH) released financials for its fiscal 2018 Q3 after the close today and hosted a conference call for investors and analysts. Readers can access a full...
- August 7th, 2018 at 11:24 pm

GW Pharma Epidiolex FDA Decision Date Set for June 27th

GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) —...
- December 28th, 2017 at 7:25 am

GW Pharma Expects FDA Decision on Epidiolex in Mid-2018

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress Epidiolex® (cannabidiol) NDA Submitted to FDA Conference call today at 7:30 a.m. EST LONDON...
- December 4th, 2017 at 7:42 am

GW Pharma Progresses Towards Epidiolex FDA Submission

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
- December 5th, 2016 at 7:39 am